Oral Induction of Mucosal and Systemic Antibodies Against HIV-1 gp41 MPER
Oral Induction of Mucosal and Systemic Antibodies Against HIV-1 gp41 MPER
批准号:
8790302
负责人:
Gregg A Dean
金额:
$22.31万
依托单位国家:
美国
项目类别:
财政年份:
2014
资助国家:
美国
项目状态:
已结题
起止时间:
2014-08-01 至 2016-07-31
关键词:
AddressAdjuvantAntibodiesAntibody FormationAntigensB-LymphocytesBindingDataEpitheliumEpitopesFlagellinHIVHIV Envelope Protein gp41HIV-1HLA-DR AntigensHumanImmuneImmune responseImmune systemImmunizationImmunoglobulin AImmunoglobulin Class SwitchingImmunoglobulin GIn VitroInfectionInterleukin-1IntestinesKnockout MiceLactobacillus acidophilusMembraneModelingMucosal ImmunityMucous MembraneMucous body substanceMusNatureOralOral mucous membrane structureOrganismPassive Transfer of ImmunityPeptidesPolymeric Immunoglobulin ReceptorsProbioticsProteinsRecombinantsRiskRouteSalmonellaSerumSexual TransmissionSideSurfaceT cell responseT-LymphocyteTNFSF5 geneTestingTransgenic OrganismsVaccinationVaccine DesignVaccinesVaginaVirusbaseefficacy trialgp160interestmouse modelmucosal vaccinationmucosal vaccineneutralizing antibodynovelpublic health relevanceresponsetransmission processvaccination strategyvaccine efficacyvaccine evaluation
中文摘要
描述:到目前为止,没有疫苗策略成功诱导有效的广泛中和抗体(BnAb)抗HIV-1。体外分析、被动抗体转移研究和RV 144疫苗有效性试验中的抗体应答分析表明,非中和抗体可能有助于预防HIV-1传播。HIV-1 Env MPER中的三个线性区域V2和V3被认为是保护性非中和抗体的潜在靶标。我们已经构建了一种新型的重组嗜酸乳杆菌疫苗平台,其经口递送并诱导针对插入细菌表面层蛋白的MPER肽的抗原特异性粘膜伊加和全身IgG。我们已经开发了两种不同的佐剂用于重组L。嗜酸乳杆菌、IL 1?和鞭毛蛋白(FliC)。Specifi Aim 1将确定用于粘膜免疫的最佳佐剂以及应答是T细胞依赖性的还是非依赖性的。具体目标2将测试表达候选MPER、V2和/或V3表位的重组嗜酸乳杆菌是否可以在HLA-DR转基因(DRAG)人源化小鼠模型中诱导对阴道HIV-1攻击具有保护作用的粘膜和全身抗体应答。
英文摘要
DESCRIPTION: To date, no vaccine strategy has successfully induced potent broadly neutralizing antibodies (BnAb) against HIV-1. In vitro analysis, passive antibody transfer studies and analysis of antibody responses in the RV144 vaccine efficacy trial suggest non- neutralizing antibodies might contribute to protection against HIV-1 transmission. Three linear regions in the HIV-1 Env MPER, V2 and V3 have been implicated as potential targets of protective non-neutralizing antibody. We have constructed a novel recombinant Lactobacillus acidophilus vaccine platform that is orally delivered and induces antigen-specific mucosal IgA and systemic IgG against MPER peptides inserted into the bacterial surface layer protein. We have developed two different adjuvants for use with recombinant L. acidophilus, IL1¿ and flagellin (FliC). Specifi Aim 1 will determine the optimal adjuvant for mucosal immunization and whether responses are T-cell dependent or independent. Specific Aim 2 will test whether recombinant Lactobacillus acidophilus expressing candidate MPER, V2, and/or V3 epitopes can induce mucosal and systemic antibody responses that are protective against vaginal HIV-1 challenge in the HLA-DR transgenic (DRAG), humanized mouse model.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
MARC at Colorado State University
-
批准号:10411535
-
项目类别:
-
资助金额:$15.65万
-
财政年份:2022
-
负责人:Gregg A Dean
-
依托单位:
MARC at Colorado State University
-
批准号:10618902
-
项目类别:
-
资助金额:$31.66万
-
财政年份:2022
-
负责人:Gregg A Dean
-
依托单位:
CSU Infectious Disease Research and Response Training Program
-
批准号:10657788
-
项目类别:
-
资助金额:$46.52万
-
财政年份:2021
-
负责人:Gregg A Dean
-
依托单位:
CSU Infectious Disease Research and Response Training Program
-
批准号:10490359
-
项目类别:
-
资助金额:$46.17万
-
财政年份:2021
-
负责人:Gregg A Dean
-
依托单位:
CSU Infectious Disease Research and Response Training Program
-
批准号:10268828
-
项目类别:
-
资助金额:$21.45万
-
财政年份:2021
-
负责人:Gregg A Dean
-
依托单位:
Oral Induction of Mucosal and Systemic Antibodies Against HIV-1 gp41 MPER
-
批准号:8892070
-
项目类别:
-
资助金额:$18.59万
-
财政年份:2014
-
负责人:Gregg A Dean
-
依托单位:
International Feline Retrovirus Research Symposium
-
批准号:7927868
-
项目类别:
-
资助金额:$2.7万
-
财政年份:2010
-
负责人:Gregg A Dean
-
依托单位:
Recombinant Lactobacillus as an Oral Mucosal Vaccine Against HIV-1
-
批准号:7932516
-
项目类别:
-
资助金额:$20.74万
-
财政年份:2009
-
负责人:Gregg A Dean
-
依托单位:
Comparative Medicine and Translational Research Training Program
-
批准号:7900894
-
项目类别:
-
资助金额:$27.12万
-
财政年份:2008
-
负责人:Gregg A Dean
-
依托单位:
Comparative Medicine and Translational Research Training Program
-
批准号:7667328
-
项目类别:
-
资助金额:$25.98万
-
财政年份:2008
-
负责人:Gregg A Dean
-
依托单位:
Optimizing Immunogenicity of Lactobacillus as a Mucosal Vaccine Against HIV-1
-
批准号:7494877
-
项目类别:
-
资助金额:$22.28万
-
财政年份:2008
-
负责人:Gregg A Dean
-
依托单位:
Recombinant Lactobacillus as an Oral Mucosal Vaccine Against HIV-1
-
批准号:8208234
-
项目类别:
-
资助金额:$33.95万
-
财政年份:2008
-
负责人:Gregg A Dean
-
依托单位:
Recombinant Lactobacillus as an Oral Mucosal Vaccine Against HIV-1
-
批准号:7588810
-
项目类别:
-
资助金额:$34.59万
-
财政年份:2008
-
负责人:Gregg A Dean
-
依托单位:
Recombinant Lactobacillus as an Oral Mucosal Vaccine Against HIV-1
-
批准号:7750586
-
项目类别:
-
资助金额:$34.3万
-
财政年份:2008
-
负责人:Gregg A Dean
-
依托单位:
Recombinant Lactobacillus as an Oral Mucosal Vaccine Against HIV-1
-
批准号:7485532
-
项目类别:
-
资助金额:$34.53万
-
财政年份:2008
-
负责人:Gregg A Dean
-
依托单位:
Recombinant Lactobacillus as an Oral Mucosal Vaccine Against HIV-1
-
批准号:8412045
-
项目类别:
-
资助金额:$33.04万
-
财政年份:2008
-
负责人:Gregg A Dean
-
依托单位:
Comparative Medicine and Translational Research Training Program
-
批准号:7502342
-
项目类别:
-
资助金额:$12.9万
-
财政年份:2008
-
负责人:Gregg A Dean
-
依托单位:
Optimizing Immunogenicity of Lactobacillus as a Mucosal Vaccine Against HIV-1
-
批准号:7563270
-
项目类别:
-
资助金额:$18.6万
-
财政年份:2008
-
负责人:Gregg A Dean
-
依托单位:
In vivo significance of T-reg cells during FIV infection
-
批准号:7005510
-
项目类别:
-
资助金额:$29.2万
-
财政年份:2005
-
负责人:Gregg A Dean
-
依托单位:
In vivo significance of T-reg cells during FIV infection
-
批准号:7140574
-
项目类别:
-
资助金额:$28.51万
-
财政年份:2005
-
负责人:Gregg A Dean
-
依托单位:
海外基金